{"schema_version":"secwatch.filing_event.v1","accession":"0001070081-25-000026","form_type":"8-K","ticker":"PTCT","cik":"0001070081","company_name":"PTC THERAPEUTICS, INC.","filed_at":"2025-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.716271+00:00","generated_at":"2026-05-17T00:32:07.492089+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"PTC Therapeutics Q3 net income $15.9M, Sephience launch revenue $19.6M","bullets":["Total revenue $211.0M vs $196.8M YoY; net income $15.9M vs loss of $106.7M.","Sephience launch: $19.6M revenue (US $14.4M, ex-US $5.2M), 521 start forms from 141 prescribers, 341 patients on therapy.","DMD franchise revenue $85.9M (Translarna $50.7M, Emflaza $35.2M); Evrysdi royalties $70.8M.","Full-year 2025 revenue guidance narrowed to $750-$800M; GAAP R&D/SG&A $805-$835M.","Cash and marketable securities $1,687.8M as of Sep 30, 2025 (up from $1,139.7M at Dec 31, 2024)."],"urls":{"canonical":"https://secwatch.observer/filing/0001070081-25-000026","json":"https://secwatch.observer/filing/0001070081-25-000026.json","markdown":"https://secwatch.observer/filing/0001070081-25-000026.md","text":"https://secwatch.observer/filing/0001070081-25-000026.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1070081/000107008125000026/0001070081-25-000026-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1070081/000107008125000026/tmb-20251104x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:32:07.492089+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}